Varlilumab

Varlilumab

Monoclonal antibody
Type	?
Source	Human
Target	CD27
Clinical data
Other names	CDX-1127
ATC code	none
Identifiers
CAS Number	1393344-72-3
ChemSpider	none
UNII	0125DUV5XC
Chemical and physical data
Formula	C6486H9992N1740O2022S42
Molar mass	146043.96 g·mol^−1

Varlilumab (INN;^[1] development code CDX-1127) is a monoclonal antibody designed for immunotherapy for solid tumors and hematologic malignancies.^[2] It is an anti-CD27 antibody and helps activate T-cells.^[3]

This drug was developed by Celldex Therapeutics.

It (in combination with ONT-10) has undergone a phase 1B clinical trial for advanced breast or ovarian cancer.^[4] In combination with anti-PD-1 nivolumab it has undergone a phase 1/2 trial for advanced refractory solid tumours^[5]

References

1. World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).
2. Statement On A Nonproprietary Name Adopted By The USAN Council - Varlilumab, American Medical Association.
3. Melão A (June 2017). "Varlilumab-Opdivo Combo Stabilizes or Shrinks Tumors in 80% of Solid-cancer Patients, Trial Shows".
4. Clinical trial number NCT02270372 for "Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer" at ClinicalTrials.gov
5. Clinical trial number NCT02335918 for "A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors" at ClinicalTrials.gov